FGF19 and hepatocellular carcinoma: Because chronic FGF19 overexpression was shown to induce hepatocellular carcinoma in mice by activating STAT3 signaling [114, 115], a nontumorigenic FGF19 analogue (NGM282, also known as M70 and aldafermin) that does not activate STAT3 was developed [116].